STRATA Skin Sciences Inc., a medical technology company focused on dermatologic treatments, reported its first quarter 2025 financial results. The company achieved revenue of $6.8 million, marking a 1% increase compared to the previous year. Global net recurring XTRAC® revenue reached $4.5 million, a slight decrease from $4.6 million in the prior year period. However, this was bolstered by 27% growth in international markets, which helped offset a 4% decline in the domestic market. The company reported a net loss of $2.4 million for the first quarter of 2025, showing an improvement from a net loss of $3.4 million in the same quarter of 2024. Total operating expenses decreased by 5% to $5.7 million, with significant reductions in engineering and product development costs by 60%, selling and marketing costs by 1%, and general and administrative expenses by 5% compared to the previous year. As of March 31, 2025, STRATA Skin Sciences had cash, cash equivalents, and restricted cash totaling $7.8 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.